CDK2 and hepatocellular carcinoma: The miR-320a/PBX3 axis downregulates the expression of cyclin-dependent kinase 2 (CDK2) by targeting ERK1/2 to reduce MAPK signaling pathway activation, thus inhibiting the proliferation of HCC cells [117].